United States: RICO Indictment Of NECC Executives For Acts Of Second-Degree Murder

Last Updated: February 3 2015
Article by Michele L. Adelman and Daniel J. Procaccini

An Unprecedented Approach to Regulatory Violations

In December 2014, the United States Attorney for the District of Massachusetts obtained a sweeping indictment that charges business executives of the New England Compounding Center ("NECC") with 25 acts of second-degree murder as predicate offenses under the Racketeer Influenced and Corrupt Organizations ("RICO") Act.1 The Government's decision to pursue a RICO indictment for deaths allegedly resulting from regulatory violations is a marked departure from past practice. Query whether this case is a stark anomaly or a new approach in cases where regulatory violations allegedly resulted in death or extreme patient injury.

131-Count Indictment Charges Second-Degree Murder Based on NECC's Allegedly Unsafe, Unsanitary and Unlawful Production Practices

In September 2012, the U.S. Centers for Disease Control and the Food and Drug Administration began to investigate a nationwide outbreak of fungal meningitis.2 The agencies traced the outbreak to contaminated vials of preservative-free methylprednisolone acetate (MPA) manufactured by NECC, a compounding pharmacy located in Framingham, Massachusetts.3 According to the CDC, 751 individuals in 20 different states suffered from fungal infections after receiving injections of NECC's MPA.4 Those injections allegedly caused the death of 64 patients in 9 states.5

A little more than two years later, on December 17, 2014, a federal grand jury in the District of Massachusetts charged 14 individuals associated with NECC with a host of crimes related to the outbreak, including racketeering, conspiracy to defraud the Government, mail and wire fraud, criminal contempt, and violations of the Food, Drug and Cosmetics Act, such as introduction of adulterated and misbranded drugs into interstate commerce.6 Most seriously, the indictment charges NECC's owner and head pharmacist, Barry J. Cadden, as well as the company's supervisory pharmacist, Glenn A. Chin, with 25 predicate acts of second-degree murder under RICO.7 These charges stem from the deaths of patients in Florida, Indiana, Maryland, Michigan, North Carolina, Tennessee and Virginia.8

In its 131-count indictment, the Government alleges that from at least 2006 until approximately October 2012, the defendants knowingly made and sold numerous drugs in an unsafe manner and under unsanitary conditions while simultaneously promoting and selling their products without disclosing these issues and concealing their wrongdoing from regulators.9

According to the Government, the defendants used expired ingredients, employed improper sterilization practices, and mislabeled drugs.10 Surface and air-sampling reports allegedly produced "alert level and action-level results" showing that mold and bacteria were growing in NECC's "clean" facilities.11 Chin allegedly instructed technicians "to prioritize production over cleaning and disinfecting" and to fraudulently complete cleaning logs.12 Meanwhile, Cadden allegedly told sales representatives to say that NECC "was providing the highest quality compounded medications" with a "strictly enforced environmental monitoring program and a comprehensive end-product testing program for its drugs."13 To avoid oversight, the defendants allegedly misled regulators by claiming that they only produced drugs pursuant to valid, patient-specific prescriptions, when in fact they produced drugs in bulk.14 The indictment alleges that these acts constituted a wanton and reckless indifference to human life in violation of seven states' second-degree murder statutes.15 Thus, the indictment takes allegations that are the norm in healthcare fraud cases, and claims that these same allegations establish second degree murder.

The Government's use of the RICO statute to charge business executives with murder premised upon what is typically considered white collar fraud is a dramatic move. The few instances in which pharmaceutical providers have faced criminal charges under RICO bear little resemblance to the facts here. See, e.g., United States v. Cooper, 880 F.2d 415 (6th Cir. 1989) (affirming RICO conviction based on evidence that defendant was part of a wide-ranging, decade-long conspiracy to engage in fraudulent insurance company billing, controlled substance violations and mail fraud by more than 20 pharmacies). In the First Circuit, federal prosecutors have traditionally used RICO to target gangs or crime families involved in classic racketeering such as bribery, extortion or dealing controlled substances. See, e.g., Cianci, 378 F.3d at 86-87 (affirming RICO conspiracy convictions for three city officials for acts of public corruption including several coordinated bribery schemes); United States v. Patrick, 248 F.3d 11, 19 (1st Cir. 2001) (affirming RICO convictions of members of Intervale Posse gang including predicate acts of murder and drug dealing); United States v. London, 66 F.3d 1227, 1245 (1st Cir. 1995) (affirming RICO conviction for predicate acts including illegal gambling and money laundering).

A Potential Stumbling Block:  The Enterprise Requirement  

Whether the Government will be able to sustain its burden of proof remains an open question. To prove a substantive RICO violation, "the Government must prove beyond a reasonable doubt that (1) the enterprise affected interstate or foreign commerce, (2) that the defendant under consideration associated with the enterprise, (3) that [the] defendant participated in the conduct of the enterprise's affairs, and (4) that the defendant's participation was through a pattern of racketeering activity." United States v. Shifman, 124 F.3d 31, 35 (1st Cir. 1997) (internal quotation marks omitted).16

One hurdle the Government will face in the NECC case is establishing the enterprise requirement. The Government claims that the defendants constituted a criminal enterprise "associated in fact" under RICO. "An association-in-fact enterprise is a group of persons associated together for a common purpose of engaging in a course of conduct." Boyle v. United States, 556 U.S. 938, 938 (2009). Significantly, "the enterprise must be distinct from the pattern of racketeering activity[.]" United States v. Nascimento, 491 F.3d 25, 32 (citing United States v. Turkette, 452 U.S. 576, 583 (1981)). In the First Circuit, "[a]n enterprise is chiefly distinguished from the pattern of racketeering activity by the fact that it possesses some goal or purpose more pervasive and more enduring than the instant gratification that can accrue from the successful completion of each particular criminal act." Nascimento, 491 F.3d at 32. The organization must "'function as an ongoing unit and constitute an 'ongoing organization.'" United States v. Cianci, 378 F.3d 71, 82 (2004). Although the First Circuit has declined to require that a criminal enterprise have an "ascertainable structure," id., it has considered several non-dispositive factors to determine whether an association-in-fact exists, including:

(1) whether the associates have a common purpose; (2) whether there is systematic linkage, such as overlapping leadership, structured or financial ties or continuing coordination; (3) whether there is a common communication network for sharing information on a regular basis; (5) whether the associates hold meetings and sessions where important discussions take place; (6) whether the associates wear common colors, signs or insignia to make the group identifiable; and (7) whether the group conducted common training and instruction.

In re Pharm. Indus. Average Wholesale Price Litig., 263 F. Supp. 2d 172, 182 (D. Mass. 2003) (internal citations omitted).17

In this case, the Government seeks to meet its burden of proof on the enterprise element with allegations that the defendants (1) made misrepresentations to customers about NECC's production practices; (2) produced drugs in a manner that did not comply with applicable regulations; and (3) failed to properly clean and disinfect NECC's facilities, all for the common purpose of "obtaining money and property."18 These allegations, if proven, would show some coordination and communication between the defendants. It is not clear, however, what ongoing objective or characteristics this association possessed that make it distinct from the charged predicate acts. Compare United States v. Connolly, 341 F.3d 16, 26 (1st Cir. 2003) (affirming RICO conviction where Government introduced "significant evidence of the existence of the enterprise apart from the specified racketeering acts."); Libertad v. Welch, 53 F.3d 428, 442 (1st Cir. 1995) ("As a matter of law, it is not sufficient that several organized, ongoing groups come together for one concerted action, unless those groups can also be shown to constitute a larger unit, over and above their separate structures and operations.").

From Reckless Disregard for Regulatory Standards to an Extreme Indifference to Human Life: Can the Government Bridge the Gap? 

Demonstrating that Cadden and Chin had the necessary mental state to support convictions for second degree murder may also be a significant hurdle. The indictment charges second-degree murder as defined by the statutes of seven different states, each with its own wrinkle on the defendants' required state of mind at the time of the offense.19 North Carolina, for instance, defines second degree murder as "acting in a manner inherently dangerous to human life so recklessly and wantonly as to manifest a mind utterly without regard for human life and social duty and deliberately bent on mischief,"20 whereas Indiana requires that defendants acted only with "an awareness of a high probability that their conduct would result in death."21 The Government alleges the defendants' conduct showed "an extreme and appalling indifference to human life."22 The indictment, however, on its face suggests some contrary facts. For example, the defendants did routinely autoclave drugs to sterilize them, even if they allegedly did so for an insufficiently long period of time.23 Similarly, at least some drug samples were allegedly sent for sterility testing.24 And discovery and investigation may very well reveal other acts that will preclude the Government from meeting its burden of proof.

This not the first time that mislabeled or tainted pharmaceuticals produced by compounding pharmacies have resulted in death or serious injury. According to one review of the data, "more than two dozen deaths since 2001 have been linked to contaminated or mismeasured doses of medications produced by compounding pharmacies."25 Criminal charges in these circumstances are rare; a charge of second-degree murder has never been brought. For example, in March 2007, in the Apothécure case, three patients from the Pacific Northwest died after receiving super-potent doses of colchicine injectable solution, a drug used for the treatment and prevention of gout.26 The drugs were hundreds of times stronger than was declared on their label and had been misbranded by a Texas-based compounding pharmacy.27 The pharmacy and its owner were charged with two misdemeanor violations of violations of the Food, Drug and Cosmetics Act.28 The owner was sentenced to one year of probation and a $100,000 fine.29 Similarly, in 2011, in the Main Street Family Pharmacy case, a Tennessee compounding pharmacy and its owner pled guilty to a misdemeanor criminal violation for selling contaminated MPA—the same drug produced by NECC.30 The owner was sentenced to one year of probation and a $25,000 fine.31 In stark contrast, if they are convicted, Cadden and Chin face maximum sentences of life in prison.32

The Government's use of the RICO statute in United States v. Cadden to charge 25 acts of second-degree murder as predicate offenses reflects an unprecedented approach to pharmaceutical regulatory violations that allegedly resulted in patient deaths. It remains to be seen whether this approach will be embraced by other jurisdictions.


1. See Indictment, United States v. Cadden et al., 1:14-cr-10363 (D. Mass.) ("Indictment"); Press Release, U.S. Attorney's Office, District of Massachusetts, 14 Indicted in Connection with New England Compounding Center and Nationwide Fungal Meningitis Outbreak at 1 (Dec. 17, 2014) (hereafter "NECC Press Release").

2. U.S. Centers for Disease Control, Multistate Outbreak of Fungal Meningitis and Other Infections, available here (last visited Jan. 11, 2015) ("CDC Report"). A compounding pharmacy produces drugs that are tailor-made to a physician's specifications to suit a particular patient. See T. R. Goldman, Health Policy Brief: Regulating Compounding Pharmacies, 33 HEALTH AFFAIRS 1 (May 1, 2014). Between 1 and 3 percent of all pharmaceuticals are compounded. Id.

3. NECC Press Release at 1.

4. See id.; see also CDC Report at 1.

5. See NECC Press Release at 1; CDC Report at 1.

6. See generally Indictment.

7. NECC Press Release at 1.

8. Id.

9. Id. at 3.

10. See id.; see also Indictment ¶ 74.

11. Indictment ¶ 37(d).

12. Id. at ¶ 37(b).

13. Id. at ¶ 35.

14. See NECC Press Release at 3; see also Indictment ¶¶ 76-108.

15. NECC Press Release at 1.

16. The Government also charged NECC executives with a racketeering conspiracy under 18 U.S.C. 1962(d). See Indictment ¶¶ 72-75. The elements of this charge are closely aligned with those of the substantive RICO count. "For a defendant to be found guilty of conspiring to violate RICO, the government must prove (1) the existence of an enterprise affecting interstate commerce, (2) that the defendant knowingly joined the conspiracy to participate in the conduct of the affairs of the enterprise, (3) that the defendant participated in the conduct of the affairs of the enterprise, and (4) that the defendant did so through a pattern of racketeering activity by agreeing to commit, or in fact committing, two or more predicate offenses." Shifman, 124 F.3d at 35 (internal quotation marks omitted)

17. "[I]t is appropriate to rely on civil RICO precedent when analyzing criminal RICO liability. The standard is the same for both criminal and civil RICO violations." Shifman, 124 F.3d at 35 n.1

18. See Indictment ¶¶ 34-37 (sections titled "The Enterprise" and "Manner and Means of the Enterprise").

19. See Indictment ¶¶ 58-62.

20. Id. at ¶ 62.

21. Id. at ¶ 58.

22. See NECC Press release at 1.

23. See Indictment ¶ 36(c).

24. See id. at ¶ 36(e).

25. See Peter Eisler, Deaths, infections tied to 'compounding' drugs, USA TODAY (Mar. 6, 2013), available here.

26. See Press Release, Department of Justice, Office of Public Affairs, U.S. Files Criminal Charges Against Dallas Company in Connection with Misbranded Drug Shipment That Led to Three Deaths (Feb. 10, 2012) ("Apothecure Release"); see also United States v. Gary D. Osborn and Apothécure Inc., 3:12-CR-047-M (N.D. Tx. Feb. 10, 2012).

27. See Apothecure Release.

28. See id.

29. See U.S. v. Osborn, Dkt. # 58.

30. See Press Release, U.S. Attorney's Office, Western District of Tennessee, Main Street Pharmacy Co-Owner Pleads Guilty To Criminal Violation Of The Federal Food, Drug, And Cosmetic Act (Dec. 11, 2011),

31. See id.

32. See NECC Press Release at 3.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions